{"id":"vaxigriptetra-by-sanofi-inc","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Injection site pain, erythema, or swelling"},{"rate":"5–15","effect":"Myalgia"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Fatigue"},{"rate":"1–5","effect":"Low-grade fever"}]},"_chembl":{"chemblId":"CHEMBL5783405","moleculeType":null,"molecularWeight":"528.36"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated (killed) influenza virus particles representing four seasonal flu strains (two A subtypes and two B lineages). When administered, it triggers both humoral and cellular immune responses, leading to the production of protective antibodies and memory immune cells that recognize and neutralize circulating influenza viruses during the flu season.","oneSentence":"VaxigripTetra is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:58.135Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children ≥6 months of age"}]},"trialDetails":[{"nctId":"NCT04523324","phase":"PHASE4","title":"Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2019-10-31","conditions":"Influenza","enrollment":577}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"VaxigripTetra™ by Sanofi, Inc.","genericName":"VaxigripTetra™ by Sanofi, Inc.","companyName":"Centers for Disease Control and Prevention","companyId":"centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"VaxigripTetra is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus. Used for Seasonal influenza prevention in adults and children ≥6 months of age.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}